News
Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate Phase 2/3 Clinical Trial in Long COVID
29 August 2023
The ESSOR study is a natural extension to our ongoing evaluation of LAU-7b as a next-generation COVID-19 therapeutic, which generated positive...
Read MoreLAU-7b featured in The Pharmaceutical Journal among next-generation antivirals targeting COVID-19
19 January 2023
LAU-7b featured in The Pharmaceutical Journal (The Royal Pharmaceutical Society) among next-generation antivirals targeting COVID-19
Read MoreEVENTS
Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
Laurent Pharma to participate to BiotechGate, February 7-9, 2022
Laurent Pharma to participate to Biotech Showcase, January 9-11 and 17-19, 2022
Laurent Pharma to participate to H.C. Wainwright 23rd Annual Global Investment Conference,
September 13-15, 2021
September 13-15, 2021